Targeting DNA Damage Repair Pathways Beyond PARP Inhibition

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The clinical success of poly (ADP-ribose) polymerase (PARP) inhibitors has spurred interest in targeting DNA damage repair (DDR) pathways for cancer treatment.
• Inhibitors of various DDR proteins are advancing into clinical trials, offering potential for targeted therapy in genomically defined cancers and overcoming PARP inhibitor resistance.

Purpose of the Study:

• To review recent clinical evidence of DNA damage repair inhibitors.
• To focus on specific DDR signaling and repair targets including ATR, ATM, DNA-PK, CHK1, WEE1, RAD51, PolƟ, WRN, USP1, and PARG.
• To discuss clinical successes, failures, challenges, and future directions for DDR inhibitors.

Main Methods:

• Literature review of clinical trial data for DDR inhibitors.
• Analysis of monotherapy and combination treatments with chemotherapy, PARP inhibitors, and other DDR inhibitors.
• Discussion of challenges and future research directions, including biomarker integration and genomic profiling.

Main Results:

• DDR inhibitors have demonstrated both successes and failures in clinical trials, as monotherapy or in combination regimens.
• The review highlights the diverse range of DDR targets being investigated, from signaling kinases to DNA repair enzymes.
• Challenges remain in fully realizing the therapeutic potential of these agents.

Conclusions:

• DNA damage repair inhibitors represent a promising therapeutic strategy in oncology, particularly when tailored to specific genetic vulnerabilities.
• Overcoming challenges through biomarker integration and genomic profiling is essential for optimizing patient selection and treatment outcomes.
• Continued research into novel DDR targets and combination strategies is warranted to fully exploit the potential of DDR inhibition in cancer therapy.